ArcovaarcovaCompare
Sign inStart for free
Compare/Arcova vs. building in-house
Resources

Arcova vs. Building In-House

Every part of what Arcova does can, in principle, be built in-house: the public record is public, and a determined team can watch it with spreadsheets and alerts, a RevOps workflow build, or a scraper stack. The honest question is not whether you could, it is whether tracking, interpreting, and maintaining life science signals is the work your team should own, because each approach does some things genuinely well and carries an ongoing cost that tends to surface later.

8 min readUpdated Jul 20, 2026

The build or buy question deserves a straight answer, because building is not a strawman: plenty of life science sales teams track signals in-house today, and some of that work is genuinely good. There are three common shapes, a spreadsheet with alerts, a RevOps workflow build, and a homegrown scraper stack, and each one solves part of the problem. What none of them gets for free is the part Arcova treats as the actual product: interpreting public activity against your ICP and keeping that interpretation current, week after week.

What does the spreadsheet and Google Alerts approach do well?

It starts today, costs nothing, and forces clarity. A rep who sets up alerts on fifty named accounts and logs what comes back learns quickly which events coincide with useful outreach, which is exactly the education signal-based GTM is built on. For a short, stable account list and a single owner, it can carry a team surprisingly far.

It strains on coverage and consistency. Keyword alerts only catch events that phrase themselves the way you guessed, and a spreadsheet is only as current as its last edit. The moment the list grows past what one person can re-check weekly, the misses become invisible: you do not see the funding round you did not catch.

What does a RevOps workflow build do well?

A skilled RevOps team using a general-purpose enrichment and workflow platform can automate real coverage: waterfall enrichment, scheduled checks on funding and hiring, AI prompts that approximate fit logic. This is the strongest in-house shape, and our Arcova vs. Clay comparison takes it seriously: yes, in principle a technical team can build a life science signal pipeline this way, and a team that already runs broad GTM automation across several use cases gets real leverage from owning the canvas.

The strain is that every life science-specific rule, what counts as therapeutic area match, which trial events matter at which stage, when a hiring pattern means budget, has to be designed, tested, and maintained by hand, and it decays as sources and edge cases change. The build is a project; the maintenance is a job.

What does a homegrown scraper stack do well?

For one well-defined source, a saved query on a public trial registry, a watcher on a federal database, scraping is cheap and exact, and an engineering team gets precisely the field it wants. If your entire signal need is one source and one question, a small script may honestly be the right answer.

The strain arrives with breadth and time. Life science readiness lives across many public sources, registries, regulatory calendars, funding announcements, conference exhibitor lists, hiring pages, each with its own format and its own habit of changing without notice. A stack that watches all of them is a standing engineering commitment, and the output is still raw events: someone must then decide what each one means for each account, which is the judgment half of the problem and the harder half to staff.

Genuinely good atWhere it strains
Spreadsheet + alertsFree, immediate, teaches you your real signalsCoverage gaps and staleness as the list grows
RevOps workflow buildReal automation, full control of the logicLife science rules built and maintained by hand
Homegrown scraper stackExact answers from a single known sourceBreadth, source drift, and raw events without interpretation
ArcovaFit and readiness scored out of the box, kept currentNot a general-purpose platform for non-life science work

When is building in-house the better fit?

Honestly: when the need is narrow, the team is technical, or the learning is the point. A team whose entire motion hangs on one signal from one source is well served by a small script. A company with spare data engineering capacity and differentiated internal data, say, proprietary usage or lab data no vendor can see, may want an in-house layer because its edge lives in data nobody else has. And an early team with more time than budget learns its market faster by watching it manually for a quarter than by outsourcing the watching on day one. Arcova's case is strongest when the account list is long, the signal need spans many sources, and the team would rather spend its engineering on product than on GTM plumbing.

Using them together: in-house and Arcova are not exclusive. Teams keep their own alerts on a handful of strategic named accounts, or feed internally sourced accounts into Arcova for fit scoring and readiness monitoring, letting the homegrown layer do what it is uniquely positioned to do and Arcova carry the breadth.

Related comparisons

See how Arcova compares to Clay, Zymewire, and ZoomInfo as well.

Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →

Frequently asked questions

Could I build what Arcova does in-house?

In principle, yes. The sources are public, and a technical team could wire up feeds and alerts, write logic to approximate fit scoring, and build monitoring for funding, hiring, trial, and regulatory events. In practice the build is the smaller half of the work: sources change format, edge cases accumulate, and every signal still has to be interpreted, deciding what a phase transition or a facility announcement means for this account, which is judgment work, not plumbing. That build-and-maintain cycle is exactly the work Arcova has already done and keeps current, so the build or buy question is really about whether that maintenance is a good use of your team.

Is a spreadsheet with Google Alerts enough to track life science buying signals?

For a small, stable account list it can be a genuinely reasonable start, and it teaches a team what its real buying signals are. It strains in two predictable places: coverage, because keyword alerts miss events that never phrase themselves the way you guessed, and consistency, because the spreadsheet is only as current as the last person who updated it. Most teams outgrow it when the account list gets too long to re-check by hand each week.

What does building signal tracking in-house actually cost?

The visible cost is build time; the real cost is the standing commitment afterward. Someone has to own the pipeline when a source changes format, tune the logic as edge cases appear, and keep the interpretation layer current as your ICP evolves. That is an ongoing slice of engineering or RevOps capacity, spent on infrastructure rather than on pipeline, and it is the line item that in-house estimates most often leave out.

Related reading

Reference

Signal-based GTM

Signal-based GTM for life science targets and times outreach using public, industry-specific buying signals such as funding, hiring, clinical trial milestones, regulatory events, and publications, rather than static firmographics or generic intent data.

Guides

Biotech and pharma buying signals

A working framework for life science buying signals: which events point to new budget or new work to outsource (funding, clinical and regulatory milestones, hiring, expansion), and which fill in the picture around them.

How-to

How to score account fit

A step-by-step method for scoring company and buyer fit in life science sales: define the ICP layers, pick criteria you can actually check, score and band accounts, and act on each band.

See it on your own market

Score the accounts you already have against your ICP.

Bring in the data you already work with, from your CRM or the providers you already use, and Arcova scores it against your ICP, watches for the life science signals that matter, and tells you who is ready for outreach and why.

Start for free
HomeResourcesArcova SignalsCompareHelp centerPrivacyTermsContact
© 2026 Arcova. All rights reserved.